WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

Ja, ist schon heftig und war mir gar nicht so bewusst. Die WuXi Bio ist da wahrscheinlich die beliebtere von den beiden. Ich muss auch gestehen, dass ich bisher öfter die WuXi Bio aufgestockt habe und die AppTec etwas stiefmütterlicher behandele 🙃. Missen möchte ich die AppTec aber auch nicht.

Das kann sich eigentlich nur durch mehr Liquidität und mehr handeln ändern

Bei einer Aktie, die 18 € kostet

Also über 1 € Spread ist schon fies

Habe es nicht beobachtet bzw drauf geachtet. Hast du es mal zwischen 9 und 10 Uhr getestet? Dann ist hier 'normale' Handelszeit und Hongkong auch noch geöffnet. Vielleicht einen Versuch wert.

gibt es eine Zeit in der der Spread mal nicht allzu hoch ist? Hast du das mal beobachtet

Na dann kann es ja weiter gehen.

WuXi AppTec (02359) issued 427 million A shares and 63.155 million H shares based on the capitalization of capital reserves https://finance.sina.cn/hkstock/gsxw/2021-06-08/detail-ikqcfnaz9881172.d.html?from=wap WuXi AppTec  (02359) issued an announcement to issue 427 million A shares and 63.155 million H shares for the issuance of 2020 capitalized shares based on the conversion of capital reserves in 2020 to take effect on June 8, 2021. In addition, based on the conversion and issuance of 58,900 H shares based on the $300 million zero coupon convertible bonds maturing in 2024, the issue price per share is HK$79.85, a 52.58% discount to the closing price of HK$168.4 per share on June 7.

Jepp

Die Stockdividende ist schon mal angekommen.

Morgan Stanley: To WuXi AppTec (02359) "overweight" rating target price raised to 198 Hong Kong dollars https://m.jrj.com.cn/madapter/hk/2021/05/25103732815475.shtml Zhitong Finance APP learned that Morgan Stanley released a research report and assigned WuXi AppTec (02359) an "overweight" rating, and the target price was raised from 187 Hong Kong dollars to 198 Hong Kong dollars. According to the report, the company's performance in the first quarter was better than expected, and the mainland market's revenue growth rate was relatively high. The bank accordingly raised its 2021-24 profit forecast by 1% to 3%, considering the industry prospects attractive. Based on past performance, the market expects that once the company's products are approved, it will generate zero-cost licensing fee income, and the core business fundamentals are also stable, so there is a certain premium.

WuXi AppTec (02359 HK) adjusts 2018 A-share incentive plan https://www.finet.hk/newscenter/news_content/60a6dc33bde0b3583c917305 WuXi AppTec (02359 HK) announced that the 2020 profit distribution plan will be held at the company’s 2020 annual general meeting on May 13, 2021, the first 2021 H-share class general meeting and 2021 It was approved by shareholders at the 1st A-share Class Shareholders' Meeting in 2016. According to the 2020 profit distribution plan, the company uses the capital reserve to transfer 2 shares to be capitalized in 2020 for every 10 existing shares to all shareholders, and distributes a cash dividend of RMB 3.63 (tax included) for every 10 shares. On May 20, 2021, the board of directors reviewed and approved the resolution on adjusting the exercise price and quantity of stock options reserved for the 2018 A-share incentive plan.

https://finance.sina.cn/hkstock/gsxw/2021-05-14/detail-ikmxzfmm2321369.d.html?from=wap WuXi AppTec (02359) announced that the company will issue capitalized shares based on the capitalization reserve on the basis of 2 additional capitalized shares in 2020 for every 10 existing shares, and it will issue capitalized shares on June 7, 2021 (record (Date) to pay a total of approximately RMB 890 million (including tax) in cash dividends to shareholders listed on the company’s register of shareholders , which is equivalent to the dividend of RMB 3.63 per 10 shares of the total issued shares on the date of this announcement ( Including taxes). Newly capitalized H shares will be issued on a pro rata basis, and any fractional shares (if any) will be rounded down to the nearest complete unit.

WuXi Biologics ... and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint venture company named WuXi XDC was established to provide end-to-end contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs). Dr. Jimmy (Jincai) Li was appointed as CEO of WuXi XDC. https://www.prnewswire.com/news-releases/wuxi-biologics-and-wuxi-sta-jointly-established-wuxi-xdc-to-provide-fully-integrated-bioconjugate-cdmo-services-301291101.html

Ein Fall für den Übersetzer, etwas ausführlicher und mit Ratings zur AppTec sowie weiteren Werten: Zhitong Daily Dahang Research Report丨 WuXi AppTec (02359) first quarter results better than expected growth momentum or will continue https://m.jrj.com.cn/madapter/hk/2021/05/03171332596272.shtml